Abstract
When comprehensively reviewing the available literature, no clear and significant associations between liraglutide and pancreatitis and/or pancreas cancer seem evident. However, a recently published analysis suggests a trend toward a slightly elevated risk of pancreatitis with GLP-1 receptor agonists (including liraglutide), which may become statistical significant as more data become available. Well-established side effects are of gastrointestinal origin, typical mild-to-moderate and of transient character. The risk of hypoglycemia associated with liraglutide treatment is low.
Keywords
LiraglutideMedicinePancreatitisType 2 diabetesIncretinPancreatic cancerExenatideCancerDiabetes mellitusPancreasHypoglycemiaHereditary pancreatitisInternal medicineAdverse effectAcute pancreatitisGastroenterologyEndocrinology
Affiliated Institutions
Related Publications
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
Objectives To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight. Design Meta-analysis of available data from...
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Incretin-based therapies, including the use of incretin mimetics of glucagon-like peptide-1 receptor (GLP-1R) agonists and incretin enhancers of dipeptidyl-peptidase 4 (DPP-4) i...
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Over the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin ...
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog developed for type 2 diabetes. Long-term liraglutide exposure in rodents was associated with thyroid C-cell hyperplasia a...
Glucagon-like peptide 1 (GLP-1)
The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimu...
Publication Info
- Year
- 2014
- Type
- review
- Volume
- 14
- Issue
- 1
- Pages
- 171-180
- Citations
- 28
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
28
OpenAlex
Cite This
Thor Ameri Chalmer,
Thomas Almdal,
Tina Vilsbøll
et al.
(2014).
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer.
Expert Opinion on Drug Safety
, 14
(1)
, 171-180.
https://doi.org/10.1517/14740338.2015.975205
Identifiers
- DOI
- 10.1517/14740338.2015.975205